---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000030"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:45:04.505837+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moderna and Immatics announce $120M upfront oncology collaboration for TCR bispecifics and cancer vaccines

## Summary
- Immatics receives $120M upfront plus research funding; milestones could exceed $1.7B plus tiered royalties on net sales.
- Collaboration spans three pillars: mRNA-expressed TCER bispecifics, novel mRNA cancer vaccines using XPRESIDENT, and IMA203 TCR-T combo with Moderna's PRAME vaccine.
- Moderna leads clinical development and commercialization of TCER and vaccine products; Immatics handles preclinical/Phase 1 for the combo study.
- Immatics holds option to enter global profit/loss share for the most advanced TCER program.
- Deal subject to customary US antitrust clearance; Moderna retains full ownership of its PRAME compound.

## SEC filing metadata
- accession: 0001682852-23-000030
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000030/0001682852-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000030/mrna-20230911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000030
- JSON: https://secwatch.observer/filing/0001682852-23-000030.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.